文献速递肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌前列腺癌

肌少性肥胖及其对泌尿系肿瘤预后影响的系统综述

Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review.
PubMed 文献 · J Urol · 2021-05-25

该系统综述检索2010年1月至2021年2月文献,纳入15项研究共3866例接受治疗的肾细胞癌、尿路上皮癌和前列腺癌患者,评估肌少性肥胖的患病率及预后影响。肌少性肥胖与总生存、肿瘤特异性生存和无进展生存的关联结果不一,平均患病率为27%(范围11-63),定义方法异质性大,现有数据有限。

要点

  • 肌少性肥胖在泌尿系肿瘤患者中平均患病率为27%(范围11-63)。
  • 肌少性肥胖与总生存、肿瘤特异性生存的关联研究结果不一致。
  • 现有文献对肌少性肥胖的定义方法存在显著异质性。

核心结论

  • 文献中肌少性肥胖定义方法异质性大,现有数据有限,需进一步研究其与泌尿系肿瘤临床轨迹的关系。

研究设计与样本

  • 系统综述检索EMBASE、PubMed/MEDLINE和Scopus,纳入2010年1月至2021年2月发表的原始文章和摘要,共15项研究、3866例患者。

主要发现

  • 10项评估生存结局的研究中,肌少性肥胖与生存的关联结果不一。
  • 1项研究显示肌少性肥胖与总生存显著相关(HR 0.7,95%CI 0.51-0.98;p=0.04)。
  • 另1项研究报道肌少性肥胖与更短总生存的趋势相关(p=0.05)。
  • 其他研究报道肌少性肥胖是肿瘤特异性生存的不良预后因素(HR 5.0,95%CI 1.4-16.7;p=0.01)。
  • 其余研究未证明肌少性肥胖与总生存、肿瘤特异性生存和无进展生存有预后相关性。

关键数值与推荐

  • 肌少性肥胖平均患病率为27%(范围11-63)。

临床怎么用

  • 临床应关注泌尿系肿瘤患者的肌少性肥胖评估,但需注意定义不统一导致证据解释受限。

局限性

  • 文献中肌少性肥胖定义方法存在显著异质性,当前数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Sarcopenia, an age-related loss of muscle mass and function, may predict adverse outcomes for patients with urological cancers. However, the clinical implications and significance of sarcopenic obesity are not well understood. We systematically reviewed data on the prevalence and prognostic impact of sarcopenic obesity for patients with renal cell carcinoma, urothelial carcinoma and prostate cancer undergoing treatment. MATERIALS AND METHODS: We searched EMBASE®, PubMed®/MEDLINE® and Scopus® for relevant original articles and abstracts published between January 2010 and February 2021. Primary outcomes were overall survival (OS), cancer-specific survival (CSS) and progression-free survival. The secondary outcome was the prevalence of sarcopenic obesity. RESULTS: A total of 15 studies comprising 3,866 patients were included. Of the 10 studies that evaluated survival outcomes, the association between sarcopenic obesity and survival was mixed. One of 10 studies showed a significant association of sarcopenic obesity with OS (HR 0.7, 95% CI 0.51-0.98; p=0.04). One additional study showed reported a trend for shorter OS (p=0.05) associated with sarcopenic obesity. Others reported that it is an adverse prognostic factor for CSS (HR 5.0, 95% CI 1.4-16.7; p=0.01). All other studies did not demonstrate that sarcopenic obesity was of prognostic relevance with regard to OS, CSS and progression-free survival. Overall, its mean prevalence was 27% (range 11-63). CONCLUSIONS: There is considerable heterogeneity in methods used to define sarcopenic obesity in the literature, and current data are limited. Future studies are needed to further understand the relationship of obesity and sarcopenia on the clinical trajectory of patients with urological cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stangl-Kremser J, Mari A, Lai LY, et al. Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review. J Urol. 2021. PMID: 34032495. doi:10.1097/JU.0000000000001873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。